Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-0.48%
SPX
-0.32%
IXIC
-0.03%
FTSE
-0.09%
N225
+1.03%
AXJO
+0.51%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Overview

Loading chart...
Join our newsletter to keep up to date with us!

Key Stats

Market Cap
59.29M
Dividend Yield
0.00%
P/E Ratio
-17.05
EPS
-0.27
Revenue
700.00K
Avg. Volume
526.88K

Recently from Cashu

publisher logo
Cashu

Durect Under Legal Scrutiny Amid Acquisition Talks with Bausch Health Companies

16 days ago
publisher logo
Cashu

Bausch Health Acquires DURECT to Enhance Therapeutic Portfolio with Innovative Solutions

about 1 month ago
publisher logo
Cashu

Bausch Health Acquires DURECT to Enhance Therapeutic Portfolio and Drive Innovation

about 1 month ago

About

What does DRRX do?
DURECT, based in Cupertino, California, develops investigational therapies, including Larsucosterol for alcohol-associated hepatitis. Its FDA-approved products include POSIMIR and PERSERIS, while employing 48 staff since its 2000 IPO.
Sector
💻 Health Care
IPO
CEO
Employees
21
Headquarters
California, USA
Website
http://www.durect.com
Stocks
Health Care
drrx
Durect
NASDAQ: DRRX
+0.02 (+0.79%)
1.925
USD
At close at Sep 05, 20:35 UTC
Summary
News
Signals
Benchmarks
Financials